vs

Side-by-side financial comparison of CARPENTER TECHNOLOGY CORP (CRS) and Insulet Corporation (PODD). Click either name above to swap in a different company.

CARPENTER TECHNOLOGY CORP is the larger business by last-quarter revenue ($811.5M vs $761.7M, roughly 1.1× Insulet Corporation). CARPENTER TECHNOLOGY CORP runs the higher net margin — 17.2% vs 12.0%, a 5.2% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 11.6%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 0.8%).

Carpenter Technology Corporation develops, manufactures, and distributes stainless steels and corrosion-resistant nickel, copper and titanium alloys as well as powdered alloys for 3D additive manufacturing. In fiscal year 2018, the company's revenues were derived from the aerospace and defense industry (55%), the industrial and consumer industry (17%), the medical industry (8%), the transportation industry (7%), the energy industry (7%), and the distribution industry (6%). The company's produ...

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.

CRS vs PODD — Head-to-Head

Bigger by revenue
CRS
CRS
1.1× larger
CRS
$811.5M
$761.7M
PODD
Growing faster (revenue YoY)
PODD
PODD
+22.2% gap
PODD
33.9%
11.6%
CRS
Higher net margin
CRS
CRS
5.2% more per $
CRS
17.2%
12.0%
PODD
Faster 2-yr revenue CAGR
PODD
PODD
Annualised
PODD
24.9%
0.8%
CRS

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
CRS
CRS
PODD
PODD
Revenue
$811.5M
$761.7M
Net Profit
$139.6M
$91.1M
Gross Margin
31.0%
69.5%
Operating Margin
23.0%
16.0%
Net Margin
17.2%
12.0%
Revenue YoY
11.6%
33.9%
Net Profit YoY
46.3%
157.3%
EPS (diluted)
$2.77
$1.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRS
CRS
PODD
PODD
Q1 26
$811.5M
$761.7M
Q4 25
$728.0M
$783.7M
Q3 25
$733.7M
$706.3M
Q2 25
$755.6M
$649.1M
Q1 25
$727.0M
$569.0M
Q4 24
$676.9M
$597.5M
Q3 24
$717.6M
$543.9M
Q2 24
$798.7M
$488.5M
Net Profit
CRS
CRS
PODD
PODD
Q1 26
$139.6M
$91.1M
Q4 25
$105.3M
$101.6M
Q3 25
$122.5M
$87.6M
Q2 25
$111.7M
$22.5M
Q1 25
$95.4M
$35.4M
Q4 24
$84.1M
$100.7M
Q3 24
$84.8M
$77.5M
Q2 24
$93.6M
$188.6M
Gross Margin
CRS
CRS
PODD
PODD
Q1 26
31.0%
69.5%
Q4 25
30.0%
72.6%
Q3 25
29.5%
72.2%
Q2 25
28.3%
69.7%
Q1 25
27.6%
71.9%
Q4 24
26.2%
72.1%
Q3 24
24.6%
69.3%
Q2 24
23.9%
67.7%
Operating Margin
CRS
CRS
PODD
PODD
Q1 26
23.0%
16.0%
Q4 25
21.3%
18.7%
Q3 25
20.9%
16.7%
Q2 25
20.1%
18.7%
Q1 25
19.0%
15.6%
Q4 24
17.6%
18.3%
Q3 24
15.8%
16.2%
Q2 24
13.6%
11.2%
Net Margin
CRS
CRS
PODD
PODD
Q1 26
17.2%
12.0%
Q4 25
14.5%
13.0%
Q3 25
16.7%
12.4%
Q2 25
14.8%
3.5%
Q1 25
13.1%
6.2%
Q4 24
12.4%
16.9%
Q3 24
11.8%
14.2%
Q2 24
11.7%
38.6%
EPS (diluted)
CRS
CRS
PODD
PODD
Q1 26
$2.77
$1.30
Q4 25
$2.09
$1.42
Q3 25
$2.43
$1.24
Q2 25
$2.21
$0.32
Q1 25
$1.88
$0.50
Q4 24
$1.66
$1.38
Q3 24
$1.67
$1.08
Q2 24
$1.85
$2.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRS
CRS
PODD
PODD
Cash + ST InvestmentsLiquidity on hand
$294.8M
$480.4M
Total DebtLower is stronger
$690.4M
$18.6M
Stockholders' EquityBook value
$2.1B
$1.3B
Total Assets
$3.7B
$3.0B
Debt / EquityLower = less leverage
0.33×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRS
CRS
PODD
PODD
Q1 26
$294.8M
$480.4M
Q4 25
$231.9M
Q3 25
$208.0M
Q2 25
$315.5M
Q1 25
$151.5M
Q4 24
$162.1M
Q3 24
$150.2M
Q2 24
$199.1M
Total Debt
CRS
CRS
PODD
PODD
Q1 26
$690.4M
$18.6M
Q4 25
$930.8M
Q3 25
$934.9M
Q2 25
$939.0M
Q1 25
$1.6B
Q4 24
$1.3B
Q3 24
$1.4B
Q2 24
$1.4B
Stockholders' Equity
CRS
CRS
PODD
PODD
Q1 26
$2.1B
$1.3B
Q4 25
$2.0B
$1.5B
Q3 25
$1.9B
$1.4B
Q2 25
$1.9B
$1.5B
Q1 25
$1.8B
$1.3B
Q4 24
$1.7B
$1.2B
Q3 24
$1.7B
$1.1B
Q2 24
$1.6B
$998.4M
Total Assets
CRS
CRS
PODD
PODD
Q1 26
$3.7B
$3.0B
Q4 25
$3.5B
$3.2B
Q3 25
$3.4B
$3.0B
Q2 25
$3.5B
$3.5B
Q1 25
$3.4B
$3.5B
Q4 24
$3.3B
$3.1B
Q3 24
$3.3B
$3.0B
Q2 24
$3.3B
$2.9B
Debt / Equity
CRS
CRS
PODD
PODD
Q1 26
0.33×
0.01×
Q4 25
0.61×
Q3 25
0.68×
Q2 25
0.64×
Q1 25
1.21×
Q4 24
1.07×
Q3 24
1.21×
Q2 24
1.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRS
CRS
PODD
PODD
Operating Cash FlowLast quarter
$113.8M
Free Cash FlowOCF − Capex
$89.5M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
1.25×
TTM Free Cash FlowTrailing 4 quarters
$415.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRS
CRS
PODD
PODD
Q1 26
$113.8M
Q4 25
$132.2M
$183.3M
Q3 25
$39.2M
$125.7M
Q2 25
$258.1M
$196.5M
Q1 25
$74.2M
$63.8M
Q4 24
$67.9M
$147.7M
Q3 24
$40.2M
$98.5M
Q2 24
$169.5M
$96.5M
Free Cash Flow
CRS
CRS
PODD
PODD
Q1 26
$89.5M
Q4 25
$85.9M
$48.2M
Q3 25
$-3.4M
$100.1M
Q2 25
$200.2M
$177.9M
Q1 25
$34.0M
$51.5M
Q4 24
$38.6M
$94.1M
Q3 24
$13.3M
$71.8M
Q2 24
$141.8M
$74.0M
FCF Margin
CRS
CRS
PODD
PODD
Q1 26
11.8%
Q4 25
11.8%
6.2%
Q3 25
-0.5%
14.2%
Q2 25
26.5%
27.4%
Q1 25
4.7%
9.1%
Q4 24
5.7%
15.7%
Q3 24
1.9%
13.2%
Q2 24
17.8%
15.1%
Capex Intensity
CRS
CRS
PODD
PODD
Q1 26
3.2%
Q4 25
6.4%
17.2%
Q3 25
5.8%
3.6%
Q2 25
7.7%
2.9%
Q1 25
5.5%
2.2%
Q4 24
4.3%
9.0%
Q3 24
3.7%
4.9%
Q2 24
3.5%
4.6%
Cash Conversion
CRS
CRS
PODD
PODD
Q1 26
1.25×
Q4 25
1.26×
1.80×
Q3 25
0.32×
1.43×
Q2 25
2.31×
8.73×
Q1 25
0.78×
1.80×
Q4 24
0.81×
1.47×
Q3 24
0.47×
1.27×
Q2 24
1.81×
0.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRS
CRS

Aerospace and Defense$435.6M54%
Surcharge revenue$155.9M19%
Industrial and Consumer$78.1M10%
Medical$51.7M6%
Energy$50.5M6%
Distribution$20.4M3%
Transportation$19.3M2%

PODD
PODD

Omnipod$515.6M68%
International Omnipod$242.9M32%
Drug Delivery$3.3M0%

Related Comparisons